NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis $100.06 -1.44 (-1.42%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$100.08 +0.02 (+0.02%) As of 05/27/2025 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Blueprint Medicines Stock (NASDAQ:BPMC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Blueprint Medicines alerts:Sign Up Key Stats Today's Range$99.95▼$102.5250-Day Range$79.22▼$104.6452-Week Range$73.04▼$121.90Volume709,926 shsAverage Volume781,125 shsMarket Capitalization$6.46 billionP/E RatioN/ADividend YieldN/APrice Target$126.56Consensus RatingModerate Buy Company OverviewBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More… Blueprint Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreBPMC MarketRank™: Blueprint Medicines scored higher than 51% of companies evaluated by MarketBeat, and ranked 724th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageBlueprint Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -92.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -92.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 21.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.76% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 1.80%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.76% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Blueprint Medicines has recently increased by 1.80%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.29 News SentimentBlueprint Medicines has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Blueprint Medicines this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,256,490.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Stock News HeadlinesChristina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockMay 22, 2025 | insidertrades.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of StockMay 8, 2025 | insidertrades.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 28, 2025 | Paradigm Press (Ad)Zacks Research Issues Positive Outlook for BPMC EarningsMay 27 at 1:43 AM | americanbankingnews.comZacks Research Analysts Lift Earnings Estimates for BPMCMay 25 at 2:09 AM | americanbankingnews.comHead-To-Head Review: Blueprint Medicines (NASDAQ:BPMC) & Palatin Technologies (NYSE:PTN)May 19, 2025 | americanbankingnews.comBlueprint Medicines Is A Fast-Growing Small-Cap StockMay 7, 2025 | theglobeandmail.comBlueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their EstimatesMay 4, 2025 | finance.yahoo.comSee More Headlines BPMC Stock Analysis - Frequently Asked Questions How have BPMC shares performed this year? Blueprint Medicines' stock was trading at $87.22 on January 1st, 2025. Since then, BPMC stock has increased by 14.7% and is now trading at $100.06. View the best growth stocks for 2025 here. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings results on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by $0.32. The business's revenue was up 55.5% compared to the same quarter last year. Read the conference call transcript. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' top institutional investors include Vanguard Group Inc. (10.28%), Price T Rowe Associates Inc. MD (8.39%), Wellington Management Group LLP (4.76%) and T. Rowe Price Investment Management Inc. (2.02%). Insiders that own company stock include Jeffrey W Albers, Kate Haviland, Fouad Namouni, Christina Rossi, Tracey L Mccain, Michael Landsittel, Debra Durso-Bumpus, Percy H Carter, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/01/2025Today5/27/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPMC CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees640Year Founded2011Price Target and Rating Average Stock Price Target$126.56 High Stock Price Target$151.00 Low Stock Price Target$88.00 Potential Upside/Downside+26.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$67.09 million Net Margins-13.19% Pretax Margin-12.94% Return on Equity-77.49% Return on Assets-20.84% Debt Debt-to-Equity Ratio1.15 Current Ratio2.85 Quick Ratio2.80 Sales & Book Value Annual Sales$562.12 million Price / Sales11.50 Cash FlowN/A Price / Cash FlowN/A Book Value$4.67 per share Price / Book21.43Miscellaneous Outstanding Shares64,582,000Free Float61,216,000Market Cap$6.46 billion OptionableOptionable Beta0.83 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BPMC) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.